Abstract
Almost 200 million people worldwide are found to be affected by Diabetes mellitus (DM). DM is a metabolic disorder which occurs due to reduced insulin action and/or insulin secretion in the body. Reduced or inactive insulin results in imbalanced food metabolism. With the progression of disease, pathological changes like nephropathy, retinopathy and cardiovascular complications start occurring in the body. DM is mainly categorized into 2 types: type 1 DM and type 2 DM. Type 1 is generally treated through insulin replacement therapy. Type 2 DM is treated with oral hypoglycemics. Oral hypoglycemics are classified into 5 types: sulfonylureas, biguanides, α-glucosidase inhibitors, meglitinide analogues and thiazolidinediones. Conventional dosage forms of most of these drugs bear some drawbacks such as frequent dosing, short half live, and low bioavailability. Therefore, to alleviate the drawbacks associated with conventional dosage forms, efforts have been made in the area of novel and controlled drug delivery system for oral hypoglycemics. Present review highlights various novel and controlled drug delivery systems that have been investigated by different researchers for achieving sustained and controlled drug delivery of oral hypoglycemics and for overcoming the limitations related with the conventional dosage forms of oral hypoglycemics.
Keywords: Diabetics, Oral hypoglycemics, Conventional therapy, Novel Drug Delivery Systems, Sustained release, Marketed formulations.
Current Drug Delivery
Title:Recent Advances in Drug Delivery Systems for Anti-Diabetic Drugs: A Review
Volume: 11 Issue: 4
Author(s): Meenu Grover and Puneet Utreja
Affiliation:
Keywords: Diabetics, Oral hypoglycemics, Conventional therapy, Novel Drug Delivery Systems, Sustained release, Marketed formulations.
Abstract: Almost 200 million people worldwide are found to be affected by Diabetes mellitus (DM). DM is a metabolic disorder which occurs due to reduced insulin action and/or insulin secretion in the body. Reduced or inactive insulin results in imbalanced food metabolism. With the progression of disease, pathological changes like nephropathy, retinopathy and cardiovascular complications start occurring in the body. DM is mainly categorized into 2 types: type 1 DM and type 2 DM. Type 1 is generally treated through insulin replacement therapy. Type 2 DM is treated with oral hypoglycemics. Oral hypoglycemics are classified into 5 types: sulfonylureas, biguanides, α-glucosidase inhibitors, meglitinide analogues and thiazolidinediones. Conventional dosage forms of most of these drugs bear some drawbacks such as frequent dosing, short half live, and low bioavailability. Therefore, to alleviate the drawbacks associated with conventional dosage forms, efforts have been made in the area of novel and controlled drug delivery system for oral hypoglycemics. Present review highlights various novel and controlled drug delivery systems that have been investigated by different researchers for achieving sustained and controlled drug delivery of oral hypoglycemics and for overcoming the limitations related with the conventional dosage forms of oral hypoglycemics.
Export Options
About this article
Cite this article as:
Grover Meenu and Utreja Puneet, Recent Advances in Drug Delivery Systems for Anti-Diabetic Drugs: A Review, Current Drug Delivery 2014; 11 (4) . https://dx.doi.org/10.2174/1567201811666140118225021
DOI https://dx.doi.org/10.2174/1567201811666140118225021 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition
Current Vascular Pharmacology Strategies for Targeting Lentiviral Vectors
Current Gene Therapy Molecular Imaging of Vascular Inflammation
Current Pharmaceutical Design The Pharmacology of Diabetic Complications
Current Medicinal Chemistry A Novel Homologous Model for Gene Therapy of Dwarfism by Non-Viral Transfer of the Mouse Growth Hormone Gene into Immunocompetent Dwarf Mice
Current Gene Therapy Insulin Resistance, Glycemic Control and Adiposity: Key Determinants of Healthy Lifespan
Current Alzheimer Research Synthesis, Characterization and <i>in vivo</i> Evaluation of PEGylated PPI Dendrimer for Safe and Prolonged Delivery of Insulin
Drug Delivery Letters The Interplay of Marine Exposure in Gestational Diabetes
Current Women`s Health Reviews Unique Coronary Artery Disease Differences in Women as Related to Revascularization
Current Medicinal Chemistry Can Increased Food Intake Improve Psychosis? A Brief Review and Hypothesis
Current Molecular Pharmacology Intramolecular Cyclisation of β-Aryl-β-Amino Acids in the Design of Novel Heterocyclic Systems with Therapeutic Interest: An Unfailing Source of Diversity
Current Medicinal Chemistry Comparative Proteomics of Liver of the Diabetic Obese db/db and Non-Obese or Diabetic Mice
Current Proteomics PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations
Cardiovascular & Hematological Agents in Medicinal Chemistry GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges
Current Drug Targets Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?
Recent Patents on Cardiovascular Drug Discovery Green Synthesis of Silver Nanocomposites of Nigella sativa Seeds Extract for Hepatocellular Carcinoma
Current Nanomaterials Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science Pharmacological Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Obesity in China: What are the Causes?
Current Pharmaceutical Design